Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Status:
Recruiting
Trial end date:
2024-11-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy
of INCB057643 as monotherapy or combination with ruxolitinib for participants with
myelofibrosis and other myeloid neoplasms.